QCI Interpret for Oncology
Is it oncogenic? Comparing guidelines and QCI Interpret CDS for cancer variant interpretation
0 views
Accurate clinical interpretation of somatic cancer variants is critical for diagnosis and guidance of precision oncology treatment. Without shared standards, laboratories and clinical decision-support (CDS) systems have implemented independent approaches, leading to significant variability and highlighting a need for standardization.
Through a collaborative effort, ClinGen, the Cancer Genomics Consortium (CGC) and the Variant Interpretation for Cancer Consortium (VICC) have developed a framework for standardized classification. In this webinar, we will evaluate these standards and compare their classifications with results from the QIAGEN Clinical Insight (QCI) Interpret CDS system.
You will learn:
Understand ClinGen/CGC/VICC standards for variant classification
Learn how these expert-developed guidelines define and standardize somatic cancer variant classification.Compare software classifications with guideline-based human assessments
See how classifications from the ClinGen/CGC/VICC standards compare with those generated by QCI Interpret.Best practices to use guidelines and tools together
Discover how to combine expert guidelines with clinical decision support tools for more reliable variant interpretation.
Related videos
QCI Interpret for Oncology
Real-World Applications of Clinical Metagenomic Sequencing in Cancer and Infectious Disease...
Clinical metagenomic next-generation sequencing (mNGS), the comprehensive...
QCI Interpret for Oncology
Clinician’s Roundtable: Interpreting genomic test results for precision oncology
You’re invited to attend the 2024 Clinician’s Roundtable, a virtual event...
QCI Interpret for Oncology
Comprehensive Molecular Tumor Analysis with Alacris Theranostics
Precision oncology approaches have made great strides harnessing individual...
QCI Interpret for Oncology
Agilent Alissa to QCI Interpret: How can your lab reduce the stress and complexity of...
In 2023, Agilent announced the discontinuation of their Alissa Interpret...